CN101652363B - 用作激酶抑制剂的噻唑基化合物 - Google Patents

用作激酶抑制剂的噻唑基化合物 Download PDF

Info

Publication number
CN101652363B
CN101652363B CN2007800515523A CN200780051552A CN101652363B CN 101652363 B CN101652363 B CN 101652363B CN 2007800515523 A CN2007800515523 A CN 2007800515523A CN 200780051552 A CN200780051552 A CN 200780051552A CN 101652363 B CN101652363 B CN 101652363B
Authority
CN
China
Prior art keywords
substituted
ylamino
pyridine
ylthio
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800515523A
Other languages
English (en)
Chinese (zh)
Other versions
CN101652363A (zh
Inventor
安妮·马里尼尔
克劳德·奎斯尼尔
马科·多迪尔
斯蒂芬·罗伊
帕特里斯·吉尔
马克·D·威特曼
戴维·R·兰利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN101652363A publication Critical patent/CN101652363A/zh
Application granted granted Critical
Publication of CN101652363B publication Critical patent/CN101652363B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2007800515523A 2006-12-20 2007-12-19 用作激酶抑制剂的噻唑基化合物 Expired - Fee Related CN101652363B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87087206P 2006-12-20 2006-12-20
US60/870,872 2006-12-20
PCT/US2007/088124 WO2008079873A2 (en) 2006-12-20 2007-12-19 Thiazolyl compounds useful as kinase inhibitors

Publications (2)

Publication Number Publication Date
CN101652363A CN101652363A (zh) 2010-02-17
CN101652363B true CN101652363B (zh) 2013-04-17

Family

ID=39563189

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800515523A Expired - Fee Related CN101652363B (zh) 2006-12-20 2007-12-19 用作激酶抑制剂的噻唑基化合物

Country Status (6)

Country Link
US (1) US8148400B2 (OSRAM)
EP (1) EP2099794B1 (OSRAM)
JP (1) JP5225288B2 (OSRAM)
CN (1) CN101652363B (OSRAM)
NO (1) NO20092035L (OSRAM)
WO (1) WO2008079873A2 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343999B2 (en) * 2007-04-10 2013-01-01 Bristol-Myers Squibb Company Thiazolyl compounds useful as kinase inhibitors
EP2559771A3 (en) 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CN102070518B (zh) * 2011-01-24 2012-05-02 江苏先声药物研究有限公司 取代吡啶及氮杂吲哚衍生物的合成
WO2015154022A1 (en) * 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK1245260A1 (zh) 2014-12-23 2018-08-24 Dana-Farber Cancer Institute, Inc. 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN106932502B (zh) * 2015-12-31 2021-05-18 上海奥博生物医药股份有限公司 一种索拉菲尼中4-氯-2-吡啶甲酸甲酯含量的测定方法
CN107043375B (zh) * 2017-04-28 2020-03-20 江苏食品药品职业技术学院 一种制备达沙替尼及其中间体的新方法
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
KR102253652B1 (ko) * 2019-08-19 2021-05-18 주식회사 셀젠텍 신규한 암전이 억제 활성을 갖는 화합물, 이의 제조방법 및 상기 화합물을 포함하는 암 전이 및 침윤 억제, 또는 암 치료용 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069238A1 (en) * 2000-12-21 2003-04-10 Barrish Joel C. Thiazolyl inhibitors of Tec family tyrosine kinases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004028907D1 (de) * 2003-02-06 2010-10-14 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
US8343999B2 (en) * 2007-04-10 2013-01-01 Bristol-Myers Squibb Company Thiazolyl compounds useful as kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069238A1 (en) * 2000-12-21 2003-04-10 Barrish Joel C. Thiazolyl inhibitors of Tec family tyrosine kinases

Also Published As

Publication number Publication date
WO2008079873A2 (en) 2008-07-03
US8148400B2 (en) 2012-04-03
NO20092035L (no) 2009-07-15
JP2010514686A (ja) 2010-05-06
EP2099794B1 (en) 2013-05-15
CN101652363A (zh) 2010-02-17
US20100048581A1 (en) 2010-02-25
EP2099794A2 (en) 2009-09-16
WO2008079873A3 (en) 2008-10-02
JP5225288B2 (ja) 2013-07-03

Similar Documents

Publication Publication Date Title
CN101652363B (zh) 用作激酶抑制剂的噻唑基化合物
EP2049542B1 (en) Pyrrolotriazine kinase inhibitors
CN101981033B (zh) 用作激酶抑制剂的取代的咪唑并哒嗪化合物
US7531539B2 (en) Pyrrolotriazine kinase inhibitors
US7514435B2 (en) Pyrrolotriazine kinase inhibitors
CN101687874B (zh) 吡咯并三嗪激酶抑制剂
TWI399380B (zh) 抗病毒化合物
CN101679406A (zh) 用作激酶抑制剂的噻唑基化合物
CN102245610B (zh) 吡咯并三嗪激酶抑制剂
CN104837844B (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
CN102740698A (zh) 用于激酶调节的化合物和方法及其适应症
CN106661056A (zh) 作为酪蛋白激酶1δ/ε抑制剂的咪唑并哒嗪衍生物
CN104926801A (zh) 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
JP5286281B2 (ja) アミノピラゾールキナーゼ阻害剤
CN116969944A (zh) 乙氨基取代的三环杂环化合物及其组合物、制剂和用途
CN120247900A (zh) 苯基噻唑胺嘧啶衍生物及其制备方法和应用
CN116693551A (zh) 二氢吡唑氮杂卓类化合物、含其的药物组合物及其在抗肿瘤中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130417

Termination date: 20141219

EXPY Termination of patent right or utility model